Novo Nordisk Annual Report 2021
Contents
Introducing Novo Nordisk
Strategic Aspirations
Key risks
Management
Consolidated statements
Additional information.
Novo Nordisk Annual Report 2021 34
GLP-1 therapy for type 2 diabetes
Sales of GLP-1 products for type 2 diabetes
(Rybelsus, OzempicⓇ and VictozaⓇ) increased by 28% measured
in Danish kroner and by 32% at CER to DKK 53,597 million. The
GLP-1 segment's value share of the total diabetes market has
increased to 26.5% compared with 21.9% 12 months ago.
RybelsusⓇ sales increased by 158% measured in Danish kroner
and by 168% at CER to DKK 4,838 million. Sales growth was
driven by North America Operations as well as EMEA and Rest of
World. RybelsusⓇ has now been launched in 29 countries.
OzempicⓇ sales increased by 59% measured in Danish kroner
and by 64% at CER to DKK 33,705 million. Sales growth was
driven by both North America Operations and International
Operations. OzempicⓇ has now been launched in 72 countries.
VictozaⓇ sales decreased by 20% measured in Danish kroner
and by 18% at CER to DKK 15,054 million as the GLP-1 market is
moving towards once-weekly and tablet-based treatments. The
sales decline was driven by North America Operations, EMEA
and Rest of World, partially offset by higher sales in Region
China.
by North America Operations and International Operations.
SaxendaⓇ has been launched in 65 countries, and WegovyⓇ was
launched in the US in June 2021. Novo Nordisk currently has
a value market share of 77.8% of the global branded obesity
prescription drug market. The strategic aspiration for Obesity
care is to more than double reported sales from the base in
2019 of DKK 5,679 million by 2025.
Biopharm
Sales of Biopharm products increased by 1% measured in
Danish kroner and by 4% at CER to DKK 19,203 million in line
with the strategic aspiration of sustained growth in Biopharm.
The sales growth at CER was driven by both North America
Operations and International Operations. Sales growth was
driven by Rare blood disorders.
Rare blood disorders
Sales of Rare blood disorder products increased by 6%
measured in Danish kroner and by 9% at CER to DKK 10,217
million. The increasing sales were driven by the launch products
EsperoctⓇ and RefixiaⓇ as well as NovoSevenⓇ and Novo Eight®.
Insulin sales
Sales of insulin decreased by 1% measured in Danish kroner
and increased by 1% at CER to DKK 56,006 million. Sales
growth at CER was driven by increased sales in International
Operations, partially offset by declining sales in the US.
Obesity care
Sales of Obesity care products, SaxendaⓇ and
WegovyⓇ, increased by 50% measured in Danish kroner and
by 55% at CER to DKK 8,400 million. Sales growth was driven
Rare endocrine disorders
Sales of Rare endocrine disorder products decreased by 5%
measured in Danish kroner and by 2% at CER to DKK 7,303
million. The sales development was driven by North America
Operations' sales decreasing by 12% at CER, partially offset by
International Operations sales increasing by 5% at CER. Novo
Nordisk is the leading company in the global human growth
disorder market with a value market share of 36.3% compared
to 35.6% a year ago.
Sales by therapeutic area
Diabetes care
DKK
billion
150
Obesity care Biopharm Growth at CER
14%
7%
6%
2%
5%
120
90
90
60
30
2017
2018
2019
2020
2021
Sales split in Diabetes care
Insulin sales GLP-1 sales
Other diabetes care
Growth at CER
DKK
billion
120
13%
8%
4%
100
6%
4%
80
60
60
40
40
20
20
0
2017
2018
2019
2020
2021View entire presentation